Special Issue

Advances in *Streptococcus* spp. Research: Pathogenicity, Resistance, and Clinical Implications

Message from the Guest Editors

The *Streptococcus* genus includes species implicated in both human and animal diseases, as well as others used in the dairy industry. Further research is needed to explore the phenotypic and genotypic aspects of virulence and antimicrobial resistance, particularly as they relate to complex adaptation strategies to host environments. These include resistance to reactive oxygen species and neutrophil extracellular traps (NETs), survival within professional phagocytes, immune evasion, modulation of host cell signaling pathways, and induction of cell death. Moreover, the use of invasive medical devices and empirical antibiotic therapy may facilitate the dissemination of these pathogens in hospital settings. For this research topic, we welcome the submission of original research articles, mini reviews, reviews and perspectives covering streptococcal pathogenesis in human, animal and zoonotic infectious diseases.

Guest Editors

Dr. Prescilla Emy Nagao

Laboratory of Molecular Biology and Physiology of Streptococci, Institute of Biology Roberto Alcantara Gomes, Rio de Janeiro State University—UERJ, Rio de Janeiro, Brazil

Prof. Dr. Louisy Sanches Dos Santos

Laboratory of Diphtheria and Corynebacteria of Clinical Relevance, Rio de Janeiro State University, Avenue 28 de Setembro, 87-Fundos, 3° Andar, Vila Isabel, Rio de Janeiro 20551-030, Brazil

Deadline for manuscript submissions

30 November 2025

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/si/241938

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/antibiotics

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/journal/antibiotics

About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

MDPI